Tackle Erectile Dysfunction (Impotence)
[info]nuraemir
Tackle Erectile online pharmacy viagra (Impotence)

ERECTILE DYSFUNCTION
Erectile dysfunction (ED or (male) impotence) is a sexual dysfunction characterized by the inability to develop or maintain an erection of the penis

Here are few remedies for impotence:

Quit smoking.
Smoking lowers the nitric oxide in your body. As mentioned earlier, nitric oxide is the chemical in your body responsible for making the muscles of your penis relax, allowing blood to freely come in. Studies have shown that smokers have lower levels of nitric oxide in their body.

Exercise.

In a study about erectile dysfunctions in obese men, it has been found out that increased physical activity like aerobics or exercise cured 31% of erectile dysfunction problems. Keep in mind that exercise is also coupled with a good diet. The combination is a good way to increase your sexual potency.
Keep your stress level to a minimum. Stress and anxiety can make you lose focus on things. It is not uncommon that a man, stressed and worn out from work at the end of the day, usually does not have any drive left for anything else. Stress cuts off your libido, as you are more focused on the stressor instead of anything that is erotically stimulating. Stress also increases your irritability, sapping away your sexual mood instead.

Consider surgery.

There are surgical procedures that can help fix your erectile dysfunction. Vascular surgery, for example, is used to treat blocked blood flow to the pelvic area, specifically the penis, due to an injury. Penile implants involves placing a device in your penis that allows you to get an erection for as long as you want. The device is inflatable and there are semi-rigid rods to keep your penis in a rigid state.
Erectile dysfunction is an embarrassing condition, but the fact that it is treatable makes it that much tolerable. As long as you keep an active and healthy lifestyle, you should have a strong and long sexually active life ahead of you.

Impotence can be met successfully with the use of generic drugs like generic viagra, kamagra, penegra, edegra, caverta, silagra which are the replicas of the much expensive prescription drugs. These drugs allow more blood flow to the penis. As more blood flow into it and less flows out, the arteries in the penis enlarge which results in an erection.
For more info on generic viagra, kamagra, caverta see TrustPharma.com

Frigidity: A Growing Sexual Health Concern Among Women
[info]nuraemir
Having female sexual dysfunction can be bothersome, a terrible condition similar to erectile

dysfunction in men. Inadequate sexual function in women can be a complex problem that can have

many different causes. An estimated 40% of women suffer from sexual dysfunction, and might be

caused by any physical illness, or may be linked to psychological factors. This condition mainly

affects a woman's sexual health, and has symptoms including lack of sexual desire, inability to

enjoy sex, insufficient vaginal lubrication, and even failure to have an orgasm.

Also known as Female Sexual Arousal Disorder (FSAD), this condition still makes women

psychologically desire for sex, but their genital area fails to respond normally, making it

painful or impossible to have sex. When men and women normally get aroused, their genitals become

engorged with blood. For women, this results in the enlargement of the clitoris and surrounding

tissues (comparable to a male erection), secretion of vaginal lubrication, and relaxation and

widening of the vaginal opening for intercourse.

A woman's sexual health is affected by a number of other health conditions. In this case, FSAD

can result from an underlying medical condition such as high blood pressure or diabetes. This can

also be caused by certain irritations, infections, and growth in the vaginal area. It can also be

a negative physiological reaction to certain birth control methods. This condition may also be

caused by medications used to treat high blood pressure, peptic ulcers, depression, anxiety, or

cancer. Another reason may be due to a combination of physical, hormonal, or emotional changes

that occur during or after pregnancy, or while breast feeding. In addition, FSAD can also be

linked to several psychological causes including depression, poor self-esteem, sexual abuse, fear

of pregnancy, inadequate or ineffective foreplay, feelings of shame or guilt about sex, or stress

and fatigue.

For treatment of FSAD, on going research has suggested that the use of online pharmacy viagra for treating sexual

disorders in women helps increase blood flow, thereby increasing physical stimulation in the

genital area. However, researchers are still waiting for evidence that Viagra could actually work

on women. For now, physicians concentrate on eliminating medications that might have a negative

impact on a woman's sexual health. Doctors also review the effects of certain contraceptive

methods that can be a possible factor for FSAD.

For women who suffer from vaginal dryness, it is recommended for them to use lubricants before

having sexual intercourse in order to prevent pain. On the other hand, some physicians recommend

women to practice Kegel Exercises, a form of exercise that helps in developing the muscles around

the outer part of the vagina. These muscles are involved in the production of pleasurable

sensations. Adding to this, psychological counseling can also play an integral role in treating

women with sexual problems, including FSAD. Coaching in sexual foreplay as well as stimulation

techniques can also contribute to the wellness of a woman who suffers from FSAD.

Upon knowing all these, women can now become more aware of this sexual health condition that

might be experienced by many, but is often misunderstood. Consulting one's physician may be the

best way to know more about FSAD. Constant check-up sessions with the physician or gynecologist

will also help women prevent or address such a frustrating sexual condition.

Latest New Drug Approvals
[info]nuraemir
See also: cialis | 


Bystolic (nebivolol)
Date of Approval: December 17, 2007
Company: Mylan Laboratories Inc. and Forest Laboratories
Treatment for: Hypertension
Bystolic (nebivolol) is a once daily beta blocker approved for the treatment of hypertension.
Bystolic, a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension - December 18, 2007
FDA Issues Approvable Letter for Bystolic (nebivolol) for the Treatment of Hypertension - December 3, 2007
Response Submitted to FDA Approvable Letter for Hypertension Compound Nebivolol - May 1, 2007
Mylan Laboratories Receives Approvable Letter For Its Next Generation Beta-Blocker Nebivolol - June 1, 2005
FDA Extends PDUFA Action Date for Nebivolol Tablets to May 31, 2005 - February 25, 2005
Mylan's NDA for Nebivolol Accepted for FDA Review - July 1, 2004
Mylan Submits New Drug Application for Nebivolol - May 5, 2004

Kuvan (sapropterin dihydrochloride) Tablets
Date of Approval: December 13, 2007
Company: BioMarin Pharmaceutical Inc.
Treatment for: Phenylketonuria
Kuvan is the synthetic form of 6R-BH4 (tetrahydrobiopterin), a naturally occurring enzyme cofactor that works in conjunction with phenylalanine hydroxylase to metabolize phenylalanine (Phe). Kuvan is indicated for the treatment of phenylketonuria, an inherited metabolic disease caused by a deficiency of the enzyme phenylalanine hydroxylase.
BioMarin Announces FDA Approval for Kuvan - December 13, 2007
Kuvan Receives Priority Review Status from FDA - July 26, 2007
BioMarin Submits New Drug Application for U.S. Marketing Authorization of Kuvan for
Phenylketonuria (PKU) - May 24, 2007

Triesence (triamcinolone acetonide) Injectable Suspension
Date of Approval: November 29, 2007
Company: Alcon, Inc.
Treatment for: Use in Eye Surgery
Triesence is a synthetic corticosteroid indicated for visualization during vitrectomy and treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.
Alcon Receives FDA Approval of Triesence Injectable Triamcinolone Suspension for Use in Eye Surgery - December 3, 2007

Cymbalta (duloxetine) Delayed-Release Capsules
Date of Approval: August 3, 2004
Company: Eli Lilly and Company
Treatment for: Depression, Anxiety
Cymbalta is a selective serotonin and norepinephrine reuptake inhibitor (SSNRI). Cymbalta was first approved in August 2004 for the acute treatment of major depressive disorder and has since been approved for the management of neuropathic pain associated with diabetic peripheral neuropathy and for the acute treatment of generalized anxiety disorder.New Indication Approved: November 28, 2007Treatment for: Maintenance Treatment of Major Depressive DisorderCymbalta is now also approved for the maintenance treatment of major depressive disorder (MDD) in adults.
FDA Approves Cymbalta for Maintenance Treatment of Major Depressive Disorder - November 30, 2007
FDA Approves Cymbalta for Treatment of Generalized Anxiety Disorder - February 26, 2007
Cymbalta Eli Lilly and Company - Treatment for Depression - August 4, 2004
FDA Extends Action Date for Cymbalta for Continued Analysis of Already-Submitted Data - June 24, 2004

Mircera (methoxy polyethylene glycol-epoetin beta) Injection
Date of Approval: November 14, 2007
Company: Roche
Treatment for: Anemia Associated with Chronic Renal Failure
Mircera is an erythropoiesis-stimulating agent indicated for the treatment of anemia associated with chronic renal failure.
FDA Approves Mircera: First Renal Anemia Treatment in the US with Monthly Maintenance Dosing - November 15, 2007
Roche Receives Approvable Letter for Mircera in the United States - May 21, 2007
Roche Offers the FDA Additional Mircera Data - December 15, 2006
Roche Submits Application with FDA to Market C.E.R.A. - April 20, 2006

Combigan (brimonidine tartrate and timolol maleate) Ophthalmic Solution
Date of Approval: October 30, 2007
Company: Allergan Inc.
Treatment for: Intraocular Hypertension, Glaucoma
Combigan is an alpha adrenergic receptor agonist and beta adrenergic receptor inhibitor combination ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP.
Allergan, Inc. Receives FDA Approval for Combigan (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5% - October 31, 2007
Allergan Announces FDA Issues Approvable Letter for Combigan 0.2%/0.5% - December 21, 2006

Tasigna (nilotinib) Capsules
Date of Approval: October 29, 2007
Company: Novartis
Treatment for: Chronic Myelogenous Leukemia
Tasigna is a kinase inhibitor indicated for the treatment of chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (CML) in adult patients resistant to or intolerant to prior therapy that included imatinib.
Tasigna Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients with Resistance or Intolerance to Existing Therapies - October 29, 2007

Renvela (sevelamer carbonate) Tablets
Date of Approval: October 19, 2007
Company: Genzyme Corporation
Treatment for: Hyperphosphatemia of Renal Failure
Renvela (sevelamer carbonate) is a calcium-free, metal-free, non-absorbed phosphate binder indicated for the control of serum phosphorus in patients with chronic kidney disease on dialysis.
FDA Approves Genzyme's Renvela for Dialysis Patients - October 22, 2007
Genzyme Files for Approval of Sevelamer Carbonate for Patients on Dialysis - December 21, 2006

Voltaren Gel (diclofenac sodium) Topical Gel
Date of Approval: October 17, 2007
Company: Novartis AG
Treatment for: Osteoarthritis
Voltaren Gel (diclofenac sodium) is a topical gel non-steroidal anti-inflammatory (NSAID) cheap viagra indicated for the pain of osteoarthritis in joints amenable to topical treatment, such as the knees and those of the hands.
Voltaren Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis - October 22, 2007

Ixempra (ixabepilone) Injection
Date of Approval: October 16, 2007
Company: Bristol-Myers Squibb
Treatment for: Breast Cancer
Ixempra (ixabepilone) is a semisynthetic analog of epothilone B indicated for the treatment of patients with metastatic or locally advanced breast cancer.
FDA Approves Ixempra (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer - October 17, 2007
FDA Grants Priority Review for Bristol-Myers Squibb's Investigational Oncology Treatment Ixabepilone - June 19, 2007

Doribax (doripenem) Injection - formerly Doripenem
Date of Approval: October 12, 2007
Company: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Treatment for: Intraabdominal Infection, Urinary Tract Infection
Doribax is a penem antibacterial indicated for the treatment of complicated intra-abdominal and complicated urinary tract infections, including pyelonephritis.
FDA Approves Doribax for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections - October 15, 2007
New Drug Application Submitted for Investigational Antibiotic Doripenem - June 6, 2007
New Drug Application Submitted for Investigational Antibiotic Doripenem - December 15, 2006

Isentress (raltegravir) Tablets
Date of Approval: October 12, 2007
Company: Merck & Co., Inc.
Treatment for: HIV Infection
Isentress is an integrase inhibitor indicated for the treatment of Human Immunodeficiency Virus (HIV)-1 infection in combination with other antiretroviral agents.
FDA Approves of Isentress (raltegravir) - October 12, 2007
Impending FDA Approval Decision on the First HIV Integrase Inhibitor Isentress Can Have Significant Impact for Patients - October 12, 2007
FDA Advisory Committee Unanimously Recommends Accelerated Approval of Isentress (raltegravir), Merck's Investigational Oral Integrase Inhibitor, for Treatment of HIV - September 6, 2007
FDA Priority Review Granted for Isentress (raltegravir), Merck's Investigational Integrase Inhibitor for HIV - June 27, 2007

Afluria (influenza virus vaccine)
Date of Approval: September 28, 2007
Company: CSL Biotherapies
Treatment for: Influenza Prophylaxis
Afluria is an inactivated influenza virus vaccine, indicated for active immunization of persons ages 18 years and older against influenza disease.
CSL Biotherapies Announces FDA Marketing Approval of Afluria - September 28, 2007

Azor (amlodipine and olmesartan) Tablets - formerly amlodipine and olmesartan
Date of Approval: September 26, 2007
Company: Daiichi Sankyo, Inc.
Treatment for: Hypertension
Azor is a fixed-dose combination of two antihypertensives, the calcium channel blocker amlodipine besylate and the angiotensin receptor blocker olmesartan medoxomil. Azor is indicated for the treatment of hypertension.
Azor Receives FDA Approval for Treatment of High Blood Pressure - September 27, 2007
Daiichi Sankyo and Forest Laboratories Sign Letter of Intent for Co-Promotion of Azor - August 21, 2007
Daiichi Sankyo, Inc. Announces Filing of NDA for Amlodipine Besylate / Olmesartan Medoxomil Combination for the Treatment of Hypertension - November 28, 2006

Totect (dexrazoxane)
Date of Approval: September 6, 2007
Company: TopoTarget A/S
Treatment for: Anthracycline Extravasation
Totect is a topoisomerase inhibitor used as a detoxifying agent for the treatment of extravasation resulting from intravenous anthracycline chemotherapy.
Totect Approved in the United States - September 7, 2007
TopoTarget elaborates on the specific initiatives to obtain FDA approval of Totect - May 31, 2007

ACAM2000 (Smallpox (Vaccinia) Vaccine, Live)
Date of Approval: August 31, 2007
Company: Acambis Inc.
Treatment for: Smallpox Prophylaxis
ACAM2000 is live vaccinia virus smallpox vaccine intended for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection. ACAM2000 is the first biodefense vaccine to be approved as part of the US response to the 2001 bioterrorism attacks.
FDA Approves ACAM2000 Vaccine for Protection Against Smallpox - September 4, 2007

Somatuline Depot (lanreotide acetate) Injection - formerly Somatuline Autogel
Date of Approval: August 30, 2007
Company: Tercica, Inc.
Treatment for: Acromegaly
Somatuline Depot is a sustained-release injection formulation of lanreotide, a somatostatin analogue indicated for the long-term treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option.
Ipsen: Somatuline Depot Receives Marketing Approval in the United States for the Treatment of Acromegaly - August 31, 2007
FDA Accepts for Filing a New Drug Application (NDA) for Somatuline Autogel - January 15, 2007
Tercica Reports Somatuline Autogel NDA for Acromegaly Submitted to FDA - November 2, 2006

Evithrom (human thrombin)
Date of Approval: August 27, 2007
Company: Omrix Biopharmaceuticals, Ltd,
Treatment for: Bleeding
Evithrom is a highly purified human thrombin used as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques is ineffective or impractical.
FDA Approves Evithrom (human thrombin) for Topical Use in Surgery - August 28, 2007
Zingo (lidocaine hydrochloride monohydrate) Dermal PowderJect
Date of Approval: August 16, 2007
Company: Anesiva, Inc.
Treatment for: Local Anesthesia
Zingo is a needle-free, local anesthetic intradermal injection system, which provides rapid, topical, local analgesia to reduce the pain associated with venous access procedures, such as IV insertions or blood draws, in children three to 18 years of age.
Anesiva Receives FDA Approval for Zingo, a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children - August 17, 2007
Endo Comments on Notices Received From Anesiva Regarding Zingo - April 10, 2007
Anesiva Announces FDA Acceptance for Filing of Zingo New Drug Application to Reduce Pain Associated With Needle Insertion Procedures in Children - February 7, 2007
Anesiva Announces Filing of New Drug Application for Zingo to Reduce Pain Associated with Needle Insertion Procedures in Children - November 27, 2006

Selzentry (maraviroc) Tablets
Date of Approval: August 6, 2007
Company: Pfizer Inc.
Treatment for: HIV Infection
Selzentry (maraviroc) is the first in a class of drugs known as CCR5 antagonists, approved for use in combination with other antiretroviral drugs for the treatment of adults with CCR5-tropic HIV-1, who have been treated with other HIV medications and who have evidence of elevated levels of HIV in their blood (viral load).
Pfizer's Selzentry (Maraviroc) Tablets, Novel Treatment for HIV, Approved by FDA - August 6, 2007
Pfizer Receives Approvable Letter From FDA For Maraviroc - June 21, 2007
FDA Advisory Committee Recommends Accelerated Approval of Pfizer’s Maraviroc for Treatment-Experienced Patients - April 25, 2007
Pfizer's Maraviroc to Receive Accelerated Regulatory Reviews in the U.S. and Europe - February 13, 2007More...


Promotes Penis Enlargement Through Exercise
[info]nuraemir

Penis enlargement is one of the most talked about issue with the circle of man. Accordingly, the size of a man's cialis can make or break his ego. Even before, there are a lot of methods used for penis enlargement. Some have even gone to a lot of experimentations to invent pills, creams, and other medications. However, none of these products have been effectively used. To the clients' disadvantage, some products have even caused infectious side effects leading to deadly diseases. Penis enlargement has become very prominent as seen in a lot of products advertised in the market. Year after year, men who want their penis to be enlarged have increased in numbers. No certainty has been indicated as when this bandwagon will come to an end. Above all, penis enlargement becomes more of a priority than a luxury.

The most common way is by penis exercise. It is considered as the easiest and the cheapest among the methods being used. Theoretically, when exercised, the penis can grow in size significantly. Plus penis exercise can be done without hassles and disturbances. The most important part o the penis that has to be considered is the Corpora Cavernosa. It is the part that increases in size through a dedicated massage. The exercising tends to stock the blood in the Corpora Cavernosa and causes the penis to bulge. Penis exercise also results to a good ejaculation, prolonged duration of erection, increase in fertility, and a sizable penis. This method of penis enlargement has is now widely practiced by a lot of men. This is very easy to do and it is not expensive unlike the pills, tablets, and creams for penis enlargement. The method is guaranteed to be painless. Above all, this way of increasing the size of the penis is the safest and doest not exhibit any side effects.

Penis-health.com is a premiere site, which caters the needs of most man especially in penis enlargement. It offers a comprehensive site full of information including video demonstration on how to correctly exercise man's penis. The techniques are developed out of the newest technology to make a sound exercise scheme. Aside from those, most of the information is researched based conducted by experts who earned their degrees in highly distinguished institutions. Penis-health.com has been enjoying a lot of success since it started its campaign. It is a site like no other and most the methods it provides are very exclusive. With this, patrons are assured that they are the only ones who are aware of such penis exercise techniques. Aside from the famous penis enlargement, there are other services that the site offers. These include fertility development, hard erection, improvement of stamina, and straightening of the penis. More importantly, the site is easily accessed and directional information is available to guide male customers around the site. To make each clients visit significant, a forum is set up where clients can ask for questions, make suggestions, and give comments about the site. People are readily available to provide the best service and courteous responses.




The 2010 Annual Perioperative Medicine Summit Starts Today
[info]nuraemir

The annual Perioperative cialis Summit 2010 starts on March 4 in Miami:

http://periopmedicine.org and @PeriopSummit

I maintain their website for the University of Miami and Cleveland Clinic, and help with the Twitter account, hosting of PDF handouts, videos, etc.

Dr. Jaffer, Chief of Division of Hospital Medicine and Summit Director will text his own tweets at http://twitter.com/PeriopSummit

Expect multiple free handouts posted on the front page of the summit website during March 4-6, 2010 and clinical pearls and discussions on Twitter: http://periopmedicine.org and @PeriopSummit

Program and Abstracts of the 5th Annual Perioperative Medicine Summit 2010

Summit Brochure



Summary

Dr. Amir K. Jaffer and Dr. Franklin Michota, the founding Summit Directors, in collaboration with Dr. David Hepner, will direct the 5th Annual Perioperative Medicine Summit in Miami, Florida.

The course is co-sponsored by the University of Miami Miller School of Medicine and the Cleveland Clinic in collaboration with the Society for Perioperative Assessment and Quality Improvement (SPAQI).

The goal of the Summit is to enable clinicians who are actively engaged in perioperative medical care to incorporate the latest findings from clinical research into their practices so that they can improve the quality and safety of their medical care.

Map of the Meeting Location


View Larger Map
Map of Eden Roc Resort

You are viewing [info]nuraemir's journal